Todos Medical says "excited about the path in front"as it continues to build into a world-class company

Todos Medical, Ltd. (OTCQB:TOMDF) has provided a corporate update following the achievement of certain key sales and financial milestones. The in-vitro diagnostics company, which focused on distributing comprehensive solutions for coronavirus (COVID-19) screening, diagnosis and immune support, as well as developing blood tests for early detection of cancer and Alzheimer’s disease, said it is "excited about the path in front of us as we continue to build Todos Medical into a world-class company and thank all of our shareholders for their ongoing support." In the statement, Gerald E. Commissiong, president & CEO for Todos Medical commented: “The second half of 2020 and the beginning of 2021 has been an incredibly exciting time for Todos. We took on the significant task of commercializing a new lab testing business with uncertain international supply chains and stiff competition, and we were able to carve out a niche of being able to timely provide labs with comprehensive lab-based COVID testing solutions that can scale to meet the requirements of local, state and federal contracting demands. "Our focus on automation has created a commercial infrastructure able to deploy integrated solutions for labs looking to scale lab services for their core clients, and we believe the growing need for regional lab solutions in the United States will only make Todos’ turnkey solutions more attractive to existing and prospective clients.” READ: Todos Medical reveals $7.15 million in sales for the month of February 2021, representing a 38.1% month over month increase The company recently announced sales for January and February 2021 of $5.2million and $7.2 million, respectively, and disclosed that it has retired approximately $3.2 million in convertible notes. It said this increasing revenue base, coupled with significant debt reduction, is strengthening the company’s financial position at a time where it is seeing increasing demand for its automated lab solutions that will allow labs to become key players in their region. The company said it intends to continue to look to expand its client base, as well as continue to strengthen its balance sheet through debt reduction and improved financial performance in preparation for a proposed listing of the company’s shares onto a national stock exchange. Todos Medical's corporate update concluded: "We remain focused on driving revenue growth and complementing our existing product offering with natural extensions. We believe that our establishment of a strong commercial infrastructure is the key to unlocking the value of our intellectual property portfolio for our Company and its stockholders." Full details of the corporate update can be found on the company's website at the following link: https://investor.todosmedical.com/news-events/press-releases/detail/106/todos-medical-provides-corporate-update Headquartered in Rehovot, Israel, Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers.  The company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire US-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle.  And Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Contact the author at jon.hopkins@proactiveinvestors.com